Latest Product Updates and Feature Enhancements on Certara GlobalSubmit eCTD software
Certara Launches Pinnacle 21 Enterprise Plus | Press Release
Certara has launched Pinnacle 21 Enterprise Plus, a solution designed to expedite regulatory submissions by reducing the time spent on drafting mapping specifications by 50%. This platform supports i...ndustry and proprietary standards, integrates seamlessly with tools like SAS and R, and aims to streamline the creation of submission-ready datasets, enhancing efficiency for clinical and statistical programmers.
Certara has released D360 version 25.5, enhancing data visualization and analytics for drug development. Key updates include dynamic data subsets, improved sequence-based modality support, and small ...molecule analysis capabilities. The release also introduces API changes, requiring a switch to Service Tokens for authentication.
Certara Simcyp Simulator Becomes First and Only Software Platform to ...
Certara's Simcyp Simulator has become the first software platform to receive EMA qualification for PBPK modeling, allowing its use in regulatory submissions across the EU. This qualification simplifi...es the drug submission process by reducing the need for clinical DDI studies, highlighting Certara's leadership in biosimulation and innovation in model-informed drug development.
New Integral Data Repository has Powerful REST API capabilities
Certara has introduced the Integral Data Repository featuring robust REST API capabilities. This new solution enables seamless integration, advanced data access, and automation for drug development w...orkflows. The repository supports interoperability with other platforms, streamlining regulatory submissions and enhancing data-driven decision-making in pharmaceutical R&D.
Major Release of Certara GlobalSubmit Software Enhances the Regulatory Submission Process | Certara
Certara announced a major release of its GlobalSubmit software, introducing enhanced features to streamline regulatory submission processes for pharmaceutical and biotech companies. The update levera...ges advanced automation and compliance tools, improving efficiency and accuracy in electronic submissions to global health authorities. This release supports faster, more reliable drug development workflows and regulatory approvals.
Strategic Partnerships and Integrations of Certara GlobalSubmit eCTD software
Certara Announces Expansion of Clinical Technology Collaboration with Merck - TradingView
Certara has expanded its clinical technology collaboration with Merck, enhancing Merck's use of Certara's Pinnacle 21 software platform. This expansion includes a metadata repository and data standar...ds workflow management, aiming to streamline regulatory submissions and manage data standards in clinical trials.
Certara Announces Expansion of Clinical Technology ... - Morningstar
Certara expands its collaboration with Merck to enhance the use of its Pinnacle 21 software platform, incorporating a metadata repository and data standards workflow management. This collaboration ai...ms to streamline data standardization in clinical trials, addressing the growing complexity of drug development data.
Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities | Certara
Certara and Biowaived have formed a strategic partnership to expand biopharmaceutics capabilities. This collaboration aims to enhance drug development by integrating Certaras biosimulation software a...nd regulatory expertise with Biowaiveds biopharmaceutics services, supporting pharmaceutical companies in optimizing drug formulation and regulatory submissions.
Funding News and Financial Performance of Certara GlobalSubmit eCTD software
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 - TradingView
Certara will announce its second quarter 2025 financial results on August 6th, 2025, after market close. A conference call to discuss the results will follow at 5:00 PM ET.
Certara Reports Second Quarter 2025 Financial Results
Certara reported its financial results for Q2 2025, showing a 12% revenue increase to $104.6 million. Software revenue grew by 22%, while services revenue rose by 5%. The company reduced its net loss... to $2 million from $12.6 million in Q2 2024. Certara reiterated its full-year financial guidance, highlighting strong performance in biosimulation software and services.
Certara to Report Second Quarter 2025 Financial Results on August 6th ...
Certara will announce its second-quarter 2025 financial results on August 6th, 2025, after market close. A conference call will follow at 5:00 PM ET, with a live and archived webcast available on Cer...tara's investor relations website.
Certara, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Quiver Quantitative
Certara, Inc. will announce its second-quarter 2025 financial results on August 6, 2025, with a conference call scheduled for 5:00 PM ET. The call will be accessible via a live and archived webcast o...n Certara's website.
Certara Reports First Quarter 2025 Financial Results
Certara has announced its financial results for the first quarter of 2025. The report details the company's revenue, operating performance, and key financial metrics for the period. This update provi...des stakeholders with insight into Certara's business performance and market position in the life sciences technology sector.
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Certara reported first quarter 2025 results with revenue up 10% year-over-year to $106 million. Software revenue rose 18% to $46.4 million, and services revenue grew 4% to $59.6 million. Net income r...eached $4.7 million, reflecting improved profitability in drug development software and services.
Certara Reports Preliminary First Quarter 2025 Financial Results ...
Certara announced preliminary financial results for Q1 2025, reporting a 10% revenue growth to $106 million. The company also authorized a $100 million share repurchase program, reflecting confidence... in its strategy. Software revenue increased by 18%, and services revenue grew by 4%. Certara reiterated its full-year 2025 guidance and continues strategic evaluation of its regulatory services business.
Certara Reports First Quarter 2025 Financial Results | Certara
Certara announced its first quarter 2025 financial results. The company provides software solutions and advanced modeling for drug development, supporting regulatory, preclinical, clinical, and marke...t access processes.
Leadership and Executive Team Updates at Certara GlobalSubmit eCTD software
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to ...
Certara has appointed Dr. Chris Bouton as Chief Technology Officer to enhance its AI-driven in-silico drug discovery platform. Bouton, previously CEO of Vyasa Analytics, will lead the development of ...Certara's next-generation model-informed drug development platform, integrating AI and biosimulation to improve drug discovery efficiency. His leadership aims to accelerate the adoption of AI-powered biosimulation, aiding faster and more successful drug development.
Certara, Inc. Appoints Christopher Bouton, Ph.D., as Chief Technology ...
Certara, Inc. has appointed Christopher Bouton, Ph.D., as Chief Technology Officer to lead the development of a next-generation drug development platform. Bouton, who has a strong background in AI an...d drug development, will focus on integrating generative AI and biosimulation to enhance drug discovery processes. His leadership aims to improve the efficiency and success rates of therapeutic discoveries.
Certara Appoints New Head of Biometrics, Data Science, and Access | Certara
Certara has appointed a new leader for its biometrics, data science, and access division, signaling a strategic focus on advanced analytics and data-driven solutions in drug development. This executi...ve appointment aims to strengthen Certaras capabilities in biosimulation, regulatory strategy, and market access for pharmaceutical clients.
Awards, Recognitions, and Industry Achievements of Certara GlobalSubmit eCTD software
Certara Wins Great Place to Work Certification for 4th Year
Certara has earned the Great Place to Work Certification for the fourth consecutive year, recognizing its positive workplace culture and employee experience in the drug development technology sector.
